Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335777 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL8886861 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL13363641 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL144832 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL6166 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL12070284 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL7087412 | 1.00 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2MAPT | |
| Water SCHEMBL7774670 | 0.98 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT | |
| Water SCHEMBL8011422 | 0.98 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT | |
| Water SCHEMBL766860 | 0.98 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108976181-A | A kind of preparation method of amorphous Cabazitaxel | 江苏红豆杉药业有限公司 | 2018-12-11 | — | — | CN | claimed |
| EP-2247582-A2 | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME | Aventis Pharma S.A. (FR) | 2010-11-10 | — | — | EP | claimed |
| WO-2009115655-A2 | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME | AVENTIS PHARMA S.A. (FR) | 2009-09-24 | — | — | WO | claimed |
| EP-1694660-B1 | PROCESS FOR THE PREPARATION OF ANHYDROUS AND HYDRATED ACTIVE PHARMACEUTICAL INGREDIENTS (APIS); STABLE PHARMACEUTICAL COMPOSITIONS PREPARED FROM THE SAME AND USES OF SAID COMPOSITIONS | QUIRAL QUIMICA DO BRASIL (BR) | 2009-04-08 | — | — | EP | claimed |
| CN-111201223-B | Octahydrocyclopenta [ c ] pyrrole allosteric inhibitors of SHP2 | 克鲁松制药公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118021814-A | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-110621316-B | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-4293105-A1 | MATURATION AGENT | Orizuru Therapeutics, Inc. (JP) | 2023-12-20 | — | — | EP | disclosed |
| CN-113636956-A | Preparation method of docetaxel chiral side chain intermediate | 深圳市老年医学研究所 | 2021-11-12 | — | — | CN | disclosed |
| EP-3755699-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-111718316-A | Production process of docetaxel trihydrate | 无锡紫杉药业有限公司 | 2020-09-29 | — | — | CN | disclosed |
| EP-3687997-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | Relay Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2000009120-A1 | NEW USE OF TAXOID DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2000-02-24 | — | — | WO | disclosed |
| EP-0876361-A1 | 4,10$g(b)-DIACETOXY-2$g(a)-BENZOYLOXY-5$g(b),20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA G]TAX-11-ENE-13$g(a)-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME | Aventis Pharma S.A. (FR) | 1998-11-11 | — | — | EP | disclosed |
| US-5654449-A | Taxoids, their preparation and the pharmaceutical compositions which contain them | RHONE-POULENC RORER S.A. (FR) | 1997-08-05 | — | — | US | disclosed |
| WO-1997021695-A1 | 4,10β-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1-HYDROXY-9-OXO-19-NOR-CYCLOPROPA[G]TAX-11-ENE-13α-YL (2R,3S)-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DIHYDRATE, AND METHOD FOR PREPARING SAME | RHONE-POULENC RORER S.A. (FR) | 1997-06-19 | — | — | WO | disclosed |
| EP-0770070-A1 | METHOD FOR PREPARING 4-ACETOXY-2ALPHA-BENZOYLOXY-5ALPHA,20-EPOXY-1,7BETA,10BETA-TRIHYDROXY-9-OXO-TAX-11-EN-13ALPHA-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE | Aventis Pharma S.A. (FR) | 1997-05-02 | — | — | EP | disclosed |
| EP-0703909-A1 | $g(D)?6,7 -TAXOLS ANTINEOPLASTIC USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA & UPJOHN COMPANY (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1996001815-A1 | METHOD FOR PREPARING 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11-EN-13α-YL(2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE TRIHYDRATE | RHONE-POULENC RORER S.A. (FR) | 1996-01-25 | — | — | WO | disclosed |
| US-5476954-A | Condensing hydroxyl protected taxane derivative with oxazolidine derivative, decyclizing in acid medium, reacting butoxycarbonyl or benzoyl radical with amine, deprotecting, isolating, purifying product | RHONE-POULENC RORER S.A. (FR) | 1995-12-19 | — | — | US | disclosed |